Stipislav Jadrijevic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stipislav Jadrijevic has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Danko Mikulic
Solid Organ Transplant Unit, Department of Surgery, Clinical Hospital Merkur, Zajceva 19, 10 000 Zagreb, Croatia
3 shared publications - Dinka Lulic
Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, A. Kovacica 1, 10 000 Zagreb, Croatia
3 shared publications - Dunja Rogić
Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia
3 shared publications - Gorjana Erceg
Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zajceva 19, 10 000 Zagreb, Croatia
3 shared publications - Ileana Lulic
Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zajceva 19, 10 000 Zagreb, Croatia
3 shared publications - Iva Bacak Kocman
Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zajceva 19, 10 000 Zagreb, Croatia
3 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1491
Artificial Intelligence in Post-Liver Transplantation: A Scoping Review of Comparative Model Performance
Objective: To map and characterize artificial intelligence (AI) applications in post-liver transplantation (LT) care, summarize comparative performance where available, and identify methodological and translational gaps. Methods: We conducted a scoping review in accordance with PRISMA-ScR. A comprehensive search of electronic databases was performed from inception through 1 April 2025. We included primary studies evaluating AI applications in the post-LT period (model development, validation, or implementation). Comparative studies were defined as those reporting head-to-head evaluation of at least two algorithmic models for the same task with quantitative performance metrics. Single-model studies were retained for evidence mapping but analyzed separately. Reviews and the other non-primary literature were included for contextual mapping. Results: The search yielded 3088 records. After deduplication, 2408 were screened, 191 full texts were assessed, and 65 studies were included. Of these, 52 reported primary outcome data. Clinical prediction studies (n = 43) focused on graft survival, rejection, fibrosis, oncologic recurrence, mortality, and composite outcomes. Operational studies (n = 3) evaluated early warning or bedside decision-support systems, and system-level studies (n = 6) examined benchmarking, donor–recipient matching, explainability, fairness, and cross-domain modeling. Most studies were retrospective and single-center, with internal validation commonly reported and external validation uncommon. Conclusions: AI research in post-LT care is expanding, with a predominant focus on clinical prediction. However, limited external validation, heterogeneous methods, and scarce real-world implementation constrain clinical readiness. Standardized evaluation and prospective integration are needed to determine whether AI tools can support decision-making and improve post-transplant outcomes.
- 13 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1491
Open AccessArtificial Intelligence in Post-Liver Transplantation: A Scoping Review of Comparative Model Performance
Objective: To map and characterize artificial intelligence (AI) applications in post-liver transplantation (LT) care, summarize comparative performance where available, and identify methodological and translational gaps. Methods: We conducted a scoping review in accordance with PRISMA-ScR. A comprehensive search of electronic databases was performed from inception through 1 April 2025. We included primary studies evaluating AI applications in the post-LT period (model development, validation, or implementation). Comparative studies were defined as those reporting head-to-head evaluation of at least two algorithmic models for the same task with quantitative performance metrics. Single-model studies were retained for evidence mapping but analyzed separately. Reviews and the other non-primary literature were included for contextual mapping. Results: The search yielded 3088 records. After deduplication, 2408 were screened, 191 full texts were assessed, and 65 studies were included. Of these, 52 reported primary outcome data. Clinical prediction studies (n = 43) focused on graft survival, rejection, fibrosis, oncologic recurrence, mortality, and composite outcomes. Operational studies (n = 3) evaluated early warning or bedside decision-support systems, and system-level studies (n = 6) examined benchmarking, donor–recipient matching, explainability, fairness, and cross-domain modeling. Most studies were retrospective and single-center, with internal validation commonly reported and external validation uncommon. Conclusions: AI research in post-LT care is expanding, with a predominant focus on clinical prediction. However, limited external validation, heterogeneous methods, and scarce real-world implementation constrain clinical readiness. Standardized evaluation and prospective integration are needed to determine whether AI tools can support decision-making and improve post-transplant outcomes.
- Open Access
- 1 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9584
YKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.
- 1 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9584
Open AccessYKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.
- Open Access
- 28 August 2025
- Published by MDPI AG in Preprints.org
YKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.
- 28 August 2025
- Published by MDPI AG in Preprints.org
Open AccessYKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.